Stuart Hwang

Stuart Hwang, Ph.D. is a venture partner and serial entrepreneur with over 25 years in corporate development including licensing, M&A, strategic alliances, portfolio prioritization and fundraising. He has acquired broad scientific and operational experience across multiple modalities like small molecules, biologics, and ADCs in oncology, neurology, and inflammation. Prior to Remiges, he was a cofounder and Chief Business Officer of Vincerx, building its pipeline and taking it public on the NASDAQ in 2020. Prior to Vincerx, he was active in company creation as President of Digestome Therapeutics and as an advisor to multiple early stage biotechs pioneering first-in-class therapies to address unmet patient needs including T-Cure, Quadriga, and Pellepharm. Earlier, Dr. Hwang led business development at Supergen where he closed an epigenetic R&D strategic alliance with GSK, M&A with Astex Tx (resulting in Astex Pharmaceuticals (NASDAQ: ASTX)) and established the groundwork for an M&A with Otuska Pharmaceuticals. Earlier in his career, he has led various drug R&D efforts from discovery to clinical translation and validation and introducing new technologies in drug development such as deep sequencing, gene discovery and transcriptional profiling (Agilent, Celera, Cor Therapeutics). Dr. Hwang is an inventor on several patents, authored numerous publications and presented at global scientific and business conferences.

Dr. Hwang received a Biology BA with High Honors at UC Sta Cruz and a Ph.D. in Endocrinology at UC Berkeley, Cancer Research Lab under an NCI Fellowship. He completed his post-doctoral training in Cancer Genomics at UC San Francisco & LBNL as a DOE Distinguished Human Genome Postdoctoral Fellow.